Integrative Nanotechnology and Biomaterial Approaches for Targeted Diabetic Wound Regeneration

Recent advancements in drug delivery technologies, bioactive molecules, and biomaterial design have transformed the therapeutic landscape of diabetic wound management. Diabetic wounds remain a major clinical challenge due to persistent inflammation, impaired angiogenesis, and reduced tissue regeneration, primarily caused by chronic hyperglycemia and oxidative stress. Emerging nanotechnology-based systems, such as polymeric, metallic, and lipid nanoparticles, enable site-specific drug delivery with enhanced stability, biocompatibility, and sustained release, thereby improving therapeutic efficacy. Complementary nanocarrier platforms like liposomes, niosomes, hydrogels, and nanohydrogels provide a moist microenvironment essential for cell proliferation and tissue remodeling while ensuring controlled drug release for faster wound closure. Advanced strategies, including dendrimers, transferosomes, microneedle arrays, and 3D-printed scaffolds, offer personalized, minimally invasive, and adaptive therapeutic solutions. Nanoemulsions and nanocapsules facilitate effective encapsulation and transport of hydrophobic drugs, broadening their clinical applicability. Incorporating bioactive growth factors such as VEGF, PDGF, chemokines, and stem cell-derived exosomes into these systems further enhances angiogenesis, modulates inflammation, and accelerates granulation tissue formation. Meanwhile, biopolymers like collagen, chitosan, hyaluronic acid, and silk sericin serve as natural scaffolds that support cell adhesion, migration, and epithelialization. Collectively, these emerging technologies signify a paradigm shift toward integrated, patient-specific, and regenerative approaches for diabetic wound healing, addressing the limitations of conventional therapies through the synergy of nanotechnology and bioengineering.